Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive,HER2-positive advanced breast cancer (monarcHER): a randomised,open-label,phase 2 trial |
| |
| Affiliation: | 1. Dana-Farber Cancer Institute, Boston, MA, USA;2. The NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK;3. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK;4. Istituto Di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, IRCCS, Milano, Italy;5. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada;6. Memorial Sloan Kettering Cancer Center, New York, NY, USA;7. Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France;8. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea;9. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;10. Royal Marsden Hospital, London, UK;11. Breast Cancer Research Centre–WA, Nedlands, WA, Australia;12. Curtin University, Nedlands, WA, Australia;13. Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;14. The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia;15. Eli Lilly, Indianapolis, IN, USA;p. Eli Lilly, Windlesham, UK;q. Gustave Roussy, Université Paris Saclay, INSERM, Villejuif, France |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
